To study the effect of ebselen on the outcome of acute ischemic stroke.
- Ebselen (Harmokisane)Drug
Intervention Desc: Antioxidant (seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action)
Multicenter, placebo-controlled, double-blind clinical trial involving 300 patients.
Oral administration of ebselen granules suspended in water (150 mg BID) or placebo was started immediately after admission and was continued for 2 weeks.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Glasgow Outcome Scale scores at 1 month and 3 months after the start of treatment.|
|Secondary||Modified Mathew Scale and modified Barthel Index scores at 1 month and 3 months.|